Major Depressive Disorder
Conditions
Keywords
major depressive disorder, fluoxetine, Hamilton Rating Scale for Depression (HAM-D-17)
Brief summary
The purpose of this study is to identify what degree of symptom changes during the early weeks could be used to predict eventual nonresponse at week 6 among depressive inpatients taking fluoxetine.
Detailed description
Patients with major depressive disorder will receive 20 mg/day of fluoxetine for six weeks. Symptom severity was assessed by the 17-item Hamilton Depression Rating Scale (HAMD-17) at weeks 0, 1, 2, 3, 4 and 6. Stable response is defined as a reduction of 50% or more of the HAMD-17 score at week 4 and week 6 of treatment. Receiver operating characteristic curve will be used to determine the cutoff point of the percentage of HAMD-17 score reduction between stable responders and nonresponders at weeks 1, 2, 3 and 4.
Interventions
DRUGfluoxetine
fluoxetine 20 mg/d
Sponsors
Kaohsiung Kai-Suan Psychiatric Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* diagnosis of major depressive disorder * HAM-D-17 ≧17 * written informed consent
Exclusion criteria
* Comorbid of substance abuse/dependence * Comorbid with mental disorders due to general medical conditions * Past history of treatment-resistant depression * Severe physical problems * pregnant women * lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stable response was defined as a reduction of 50% or more of the HAMD-17 score at week 4 and week 6 of treatment | 6 weeks after initiation of fluxetine |
Secondary
| Measure | Time frame |
|---|---|
| CGI, GAF, Zung's Depression Scale, Short-Form 36, auditory evoked potential, psychomotor speed | 6 weeks after initiation of fluxetine |
Countries
Taiwan
Outcome results
None listed